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Prediction of Mortality after Emergent
Transjugular Intrahepatic Portosystemic
Shunt Placement: Use of APACHE II,
Child-Pugh and MELD Scores in Asian
Patients with Refractory Variceal
Hemorrhage
Objective: This study was designed to determine if existing methods of grading
liver function that have been developed in non-Asian patients with cirrhosis can
be used to predict mortality in Asian patients treated for refractory variceal hemor-
rhage by the use of the transjugular intrahepatic portosystemic shunt (TIPS) pro-
cedure.
Materials and Methods: Data for 107 consecutive patients who underwent an
emergency TIPS procedure were retrospectively analyzed. Acute physiology and
chronic health evaluation (APACHE II), Child-Pugh and model for end-stage liver
disease (MELD) scores were calculated. Survival analyses were performed to eval-
uate the ability of the various models to predict 30-day, 60-day and 360-day mortali-
ty. The ability of stratified APACHE II, Child-Pugh, and MELD scores to predict sur-
vival was assessed by the use of Kaplan-Meier analysis with the log-rank test.
Results: No patient died during the TIPS procedure, but 82 patients died dur-
ing the follow-up period. Thirty patients died within 30 days after the TIPS proce-
dure; 37 patients died within 60 days and 53 patients died within 360 days.
Univariate analysis indicated that hepatorenal syndrome, use of inotropic agents
and mechanical ventilation were associated with elevated 30-day mortality (p <
0.05). Multivariate analysis showed that a Child-Pugh score > 11 or an MELD
score > 20 predicted increased risk of death at 30, 60 and 360 days (p < 0.05).
APACHE II scores could only predict mortality at 360 days (p < 0.05).
Conclusion: A Child-Pugh score > 11 or an MELD score > 20 are predictive of
mortality in Asian patients with refractory variceal hemorrhage treated with the
TIPS procedure. An APACHE II score is not predictive of early mortality in this
patient population.
ransjugular intrahepatic portosystemic shunt (TIPS) placement is a
relatively non-invasive procedure used to relieve portal hypertension and
treat variceal bleeding in patients with advanced cirrhosis (1-4).
However, TIPS placement is associated with high early mortality when used to control
acute variceal hemorrhage, with early mortality rates reported to range from 28% to
36% (5-8).
Existing methods to grade liver function have been developed in non-Asian patients
with cirrhosis (8-12), and it is not known to what extent the existing methods can
predict mortality in Asian patients with cirrhosis. Three methods commonly used to
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Tpredict mortality in cirrhosis patients are the acute physiol-
ogy and chronic health evaluation (APACHE II) (10),
Child-Pugh (13) and model for end-stage liver disease
(MELD) (14, 15) models. These methods have been
developed by the determination of independent risk
factors for mortality with large, heterogeneous groups of
patients with the development of predictive algorithms
based on these risk factors and by testing the algorithms
prospectively on other groups of patients. The aim of the
current study was to evaluate the prognostic ability of the
APACHE II, Child-Pugh and MELD models for short-term
(30-day and 60-day) and long-term (360-day) mortality in
Taiwanese patients who underwent an emergent TIPS
procedure due to uncontrolled variceal bleeding.
PATIENTS AND METHODS
Patient Population
From August 1995 to December 2006, 107 consecutive
patients (74 males, 33 females; mean age, 56 years), who
underwent an emergent TIPS procedure for uncontrolled
variceal hemorrhage were enrolled in the study.
Emergency indications for the TIPS procedure were
defined as a patient requiring blood products within 24
hours of TIPS creation, hemodynamic instability, balloon
tamponade or obvious continued bleeding (16). In general,
patients underwent an emergency TIPS procedure at our
institution after the failure of other available therapies (e.g.
blood transfusion, pharmacological management, balloon
tamponade and endoscopic treatment). All cases were
evaluated and were initially treated endoscopically. If
available treatments were unsuccessful, the clinical
condition of patients was stabilized with blood transfusion,
pharmacological therapy and/or balloon tamponade, and a
TIPS procedure was performed immediately after obtain-
ing patient informed consent. Antibiotics were adminis-
tered when there were signs or evidence of infection such
as fever or leukocytosis, suspicion of aspiration pneumonia
or evidence of other infectious conditions such as sponta-
neous bacterial peritonitis (SBP). This study was approved
by our Institutional Review Board.
Data Collection
Clinical and laboratory data were collected retrospec-
tively from the Hospital Information System database and
through a review of medical records. Data abstracted
included the presence of ascites, encephalopathy, SBP,
bacteremia, hepatorenal syndrome and other disease or
infection. The need for mechanical ventilation or inotropic
support was noted, as was the number of units of blood
transfused before the TIPS procedure. Portal and central
venous pressure levels and the portal-systemic pressure
gradient (PSG) were also recorded. Laboratory values
analyzed included hemoglobin level, hematocrit, white
blood cell (WBC) count, platelet count, prothrombin time
(PT), international normalized ratio (INR), activated partial
thromboplastin time (APTT), serum creatinine level, blood
urea nitrogen (BUN), serum albumin level, total bilirubin
level, glutamic-oxaloacetic transaminase level, glutamic-
pyruvic transaminase level and levels of serum sodium,
potassium and chloride. APACHE II (10), Child-Pugh (13)
and MELD (14, 15) scores were calculated for all patients.
The criteria used to grade hepatic encephalopathy were
based on the West Haven classification scale. Diagnosis of
hepatorenal syndrome was based on a finding of a reduced
glomerular filtration rate in the absence of other causes of
renal failure in patients with chronic liver disease. SBP was
defined as an absolute neutrophil count in the ascitic fluid
of ≥ 250/mm
3 in the absence of a surgically treatable,
intra-abdominal source of infection. Ascites was graded as:
1) none: no ascites; 2) mild: ascites detected only on
ultrasound; 3) moderate: shifting dullness; 4) severe: tense
abdomen.
Transjugular Intrahepatic Portosystemic Shunt
Procedure
Transjugular intrahepatic portosystemic shunt
procedures were performed using techniques described
elsewhere (3) and summarized here. Under local anesthe-
sia, the right (or left) hepatic vein was selectively catheter-
ized with a 40 cm-long 9 Fr sheath using a right internal
jugular venous approach. A parenchymal tract between
the hepatic and portal veins was created with a 16-gauge
Colapinto needle (Cook, Bloomington, IN) under fluoro-
scopic guidance. After entry into the portal vein, a guide
wire, followed by a 4 Fr angiocatheter, was advanced
through the parenchymal tract into the portal venous
system. Splenic (or superior mesenteric) venography was
performed. Portal venous pressure was measured through
the angiocatheter and central venous pressure was
measured from the side-arm of the 9 Fr introducer sheath.
The parenchymal tract between the hepatic and portal
veins was dilated with an 8 mm diameter angioplastic
balloon catheter. A 10 mm in diameter Wallstent
endoprosthesis (Schneider, Minneapolis, MN) was
deployed in the tract to support the parenchymal channel.
This stent can be opened from 8 mm to 12 mm; the size is
decided by the largest balloon that is used. In order to
achieve an ideal PSG lower than 15 mmHg, it is sometimes
necessary to dilate the tract of the TIPS to 12 mm. A
higher gradient was used as the therapeutic target as all
cases were medical emergencies and the use of a lower
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Transcatheteral embolization was performed to fill the
residual varices with metallic coils or tissue adhesive
(Histoacryl; B. Braun, Melsungen, Germany). All patients
were transferred to the intensive care unit (ICU) for
monitoring. Before patient discharge, Doppler ultrasonog-
raphy was performed to confirm shunt patency. If portal
vein thrombosis was present, the portal vein was recanal-
ized.
If hemostasis was achieved after the TIPS procedure, a
baseline Doppler ultrasound study was performed before
the patient was discharged. A follow-up ultrasound
examination was performed at three-month intervals
during the first year and every six months thereafter. If
there were ultrasound signs of shunt obstruction, follow-up
portography via the shunt was performed. Dilatation of the
shunt or placement of an additional metallic stent was
performed during the follow-up intervention. If portal vein
thrombosis was identified on an ultrasound or CT scan
before the TIPS procedure, the patent or partially patent
portion of the intrahepatic portal vein was punctured from
the hepatic vein and then catheterized through the
thrombosed area of the portal vein to the splenic vein or
superior mesenteric vein under fluoroscopic guidance.
After dilatation of the tract of the TIPS and thrombosed
portal vein, the metallic stent was placed continuously
from the hepatic vein through the TIPS tract to the main
portal vein or sometimes to the splenic vein or superior
mesentery vein to produce a patent TIPS tract.
Statistical Analysis
Survival analyses were performed to evaluate the ability
of APACHE II, Child-Pugh and MELD scores to predict
30-day, 60-day and 360-day mortality. The survival period
was defined as the duration between TIPS placement and
death, or TIPS placement and the last follow-up contact.
Kaplan-Meier analysis with the use of the log-rank test was
performed to assess the ability of stratified APACHE II,
Child-Pugh and MELD scores to predict survival. Scores
were evenly divided into first, second or third tertiles.
Tertiles were utilized in the analyses to avoid assumptions
regarding linearity and to maximize statistical power.
A Cox proportional hazard model was applied for both
univariate and multivariate analyses. Univariate Cox
regressions were used to evaluate the crude effect of each
demographic characteristic, laboratory examination and
clinical feature for 30-day, 60-day and 360-day mortality.
Based on a literature review, well-known risk factors for
the prediction of mortality among patients with acute
variceal bleeding who underwent the TIPS procedure were
added to the multivariate models. Other variables found to
be significant by univariate analysis were considered as
candidate confounding factors for constructing multivariate
models. The three prognostic scores (APACHE II, Child-
Pugh and MELD) were evaluated as ways to predict
mortality. Hazard ratios with 95% confidence intervals
(CI) were estimated for each prognostic scoring system.
Statistical analyses were performed with SPSS 15.0 for
Windows (SPSS, Chicago, IL), with the significance level
set at 0.05.
Multiple receiver operator characteristic (ROC) curves
for each scoring system were estimated and C-statistics
(equivalent to the area under ROC curve) with 95% CI
were calculated to compare the validity of the three
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Table 1. Characteristics of Patients Who Underwent
Emergency TIPS Placement for Refractory Variceal
Bleeding
Variables
Mean ± SD/Number (%) 
(n = 107)
Age (years) 55.50 ± 12.33
Male 74 (69)
Etiology of liver disease
Alcoholic 26 (24)
Viral hepatitis (B and/or C) 73 (68)
Others 8 (7)
Thrombosis of portal vein 10 (9)0
Spontaneous bacterial peritonitis 6 (6)
Bacteremia 17 (16)
Hepatorenal syndrome 15 (14)
Other infections 17 (16)
Ascites
None/mild 51 (48)0
Moderate/severe 56 (52)0
Encephalopathy
None 84 (79)
I/II 19 (18)
III/IV 4 (4)
Blood transfusion units 14.7 ± 12.48
Duration of ICU stay before TIPS 
placement (days) 64 (60)
Mechanical ventilation 25 (23)
Usage of inotropic agents 21 (20)
Hemodynamics (average mmHg)
Pre-TIPS placement
Portal venous pressure 32.84 (8)000
Central venous pressure 5.79 (5)00
PSG 26.96 (8)000
Post-TIPS placement
Portal venous pressure 21.12 (6)000
Central venous pressure 9.85 (5)00
PSG 11.27 (3)000
Note.─ TIPS = transjugular intrahepatic portosystemic shunt, SD = 
standard deviation, ICU = intensive care unit, PSG = portal-systemic
pressure gradientTzeng et al.
484 Korean J Radiol 10(5), Sep/Oct 2009
Table 2. Univariate Analysis by Use of Cox Proportional Hazard Regression (n = 107) of Risk Factors for 30-day, 60-day and
360-days Mortality After Emergency TIPS Placement
Variables
30-day 60-day 360-day
Hazard Ratio (95% CI)
Age 1.00 (0.97, 1.03) 1.01 (0.98, 1.03) 1.01 (0.99, 1.04)
Gender
Male 1.00 1.00 1.00
Female 0.82 (0.37, 1.85) 0.70 (0.33, 1.49) 0.76 (0.41, 1.40)
Etiology of liver disease
Alcoholic 1.00 1.00 1.00
Viral hepatitis (B and/or C) 0.85 (0.38, 1.93) 1.11 (0.50, 2.45) 0.86 (0.47, 1.61)
Others 0.67 (0.14, 3.16) 1.05 (0.29, 3.96) 0.85 (0.28, 2.59)
Thrombosis of portal vein 
No 1.00 1.00 1.00
Yes 1.65 (0.57, 4.72) 1.30 (0.46, 3.66) 1.10 (0.44, 2.76)
SBP
No 1.00 1.00 1.00
Yes 2.03 (0.61, 6.68) 1.67 (0.51, 5.44) 1.69 (0.61, 4.68)
Bacteremia
No 1.00 1.00 1.00
Yes 2.72 (0.98, 5.27) 2.31 (1.09, 4.88)* 1.85 (0.96, 3.56)
Unknown 1.18 (0.44, 3.20) 0.93 (0.35, 2.44) 0.54 (0.21, 1.37)
Hepatorenal syndrome
No 1.00 1.00 1.00
Yes 5.03 (2.34, 10.82)* 4.47 (2.19, 9.12)* 2.98 (1.53, 5.82)*
Other infections
No 1.00 1.00 1.00
Yes 0.75 (0.26, 2.13) 0.95 (0.40, 2.27) 1.19 (0.60, 2.38)
Blood transfusion in units 1.02 (0.99, 1.04) 1.02 (1.00, 1.05) 1.02 (1.00, 1.04)
ICU stay before TIPS placement
No 1.00 1.00 1.00
Yes 1.20 (0.57, 2.53) 1.47 (0.74, 2.92) 1.19 (0.69, 2.08)
Mechanical ventilationx
No 1.00 1.00 1.00
Yes 3.61 (1.75, 7.45)* 3.27 (1.69, 6.32)* 2.92 (1.66, 5.13)*
Usage of inotropic agents
No 1.00 1.00 1.00
Yes 5.64 (2.74, 11.62)* 4.08 (2.09, 7.98)* 2.84 (1.55, 5.18)*
Hemodynamics (mmHg)
Pre-TIPS placement
Portal venous pressure 1.06 (1.02, 1.11)* 1.06 (1.01, 1.10)* 1.04 (1.01, 1.08)*
Central venous pressure 1.07 (1.01, 1.14)* 1.06 (1.00, 1.12)* 1.06 (1.01, 1.11)*
PSG 1.03 (0.98, 1.08)* 1.03 (0.99, 1.08)* 1.02 (0.98, 1.06)*
Post-TIPS placement
Portal venous pressure 1.13 (1.05, 1.21)* 1.08 (1.02, 1.16)* 1.07 (1.02, 1.32)*
Central venous pressure 1.11 (1.03, 1.18)* 1.08 (1.02, 1.16)* 1.07 (1.02, 1.13)*
PSG 1.04 (0.92, 1.17)* 1.03 (0.93, 1.15)* 0.96 (0.88, 1.05)*
Ascites
None/mild 1.00 1.00 1.00
Moderate/severe 1.81 (0.86, 3.81)* 2.18 (1.10, 4.34)* 1.82 (1.04, 3.17)*
Encephalopathy
None 1.00 1.00 1.00
I/II 3.24 (1.48, 7.09)* 2.74 (1.33, 5.65)* 2.49 (1.33, 4.64)*
III/IV 9.15 (2.65, 31.54)* 06.72 (2.00, 22.59)* 06.36 (2.24, 18.06)*
continuedindices. For pairwise comparison of ROC curves, MedCalc
for Windows, version 9.38 (MedCalc Software,
Mariakerke, Belgium) was used.
RESULTS
Patient Demographics
A total of 107 patients were enrolled in this study. The
period between acute variceal hemorrhage and TIPS
placement varied greatly (mean, 19.2 ± 68.9 hours), but
this time period was not used in later calculations as there
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Hematocrit (%) 0.91 (0.86, 0.97)* 0.93 (0.88, 0.99)* 0.95 (0.91, 1.00)*
Hemoglobin (g/dl) 0.75 (0.62, 0.90)* 0.81 (0.69, 0.95)* 0.87 (0.76, 1.00)*
WBC ( 10
3/mm
3) 1.06 (1.01, 1.12)* 1.07 (1.02, 1.12)* 1.05 (1.01, 1.10)*
Platelet ( 10
6/ml) 1.00 (0.99, 1.00)* 1.00 (0.99, 1.00)* 1.00 (0.99, 1.01)*
PT (second) 1.04 (1.02, 1.05)* 1.03 (1.01, 1.05)* 1.03 (1.01, 1.04)*
APTT (second) 1.01 (1.00, 1.02)* 1.01 (1.00, 1.02)* 1.01 (1.01, 1.02)*
INR 2.64 (1.56, 4.49)* 1.38 (1.15, 1.66)* 1.32 (1.11, 1.57)*
Creatinine (mg/dL) 1.56 (1.26, 1.94)* 1.01 (0.98, 1.04)* 1.01 (0.98, 1.03)*
BUN (mg/dl) 1.02 (1.00, 1.03)* 1.02 (1.01, 1.03)* 1.02 (1.01, 1.03)*
Na
+ (meq/L) 1.00 (0.93, 1.07)* 0.98 (0.92, 1.05)* 0.98 (0.93, 1.04)*
K
+ (meq/L) 0.97 (0.84, 1.12)* 0.98 (0.88, 1.08)* 0.97 (0.84, 1.11)*
Albumin (g/l) 0.31 (0.17, 0.55)* 0.42 (0.25, 0.71)* 0.44 (0.28, 0.69)*
Total bilirubin (μ mol/l) 1.03 (0.96, 1.10)* 1.03 (0.97, 1.09)* 1.03 (0.99, 1.08)*
GOT (U/l) 1.00 (1.00, 1.01)* 1.00 (1.00, 1.01)* 1.00 (1.00, 1.01)*
GPT (U/l) 1.00 (1.00, 1.00)* 1.00 (1.00, 1.00)* 1.00 (1.00, 1.00)*
Note.─ *Statistical significance (p < 0.05)
CI = confidence interval, SBP = spontaneous bacterial peritonitis, ICU = intensive care unit, TIPS = transjugular intrahepatic portosystemic shunt, WBC =
white blood cell, PT = prothrombin time, APTT = activated partial thromboplastin time, INR = international normalized ratio, BUN = blood urea nitrogen,
GOT = glutamic-oxaloacetic transaminase, GPT = glutamic-pyruvic transaminase, PSG = portal-systemic pressure gradient
Table 3. Mortality at 30-, 60- and 360 days after TIPS Placement as Predicted by APACHE II, Child-Pugh, and MELD scores
Evaluated by Use of Multivariate Cox Proportional Hazard Regression
Variables
30 days 60 days 360 days
Hazard Ratio (95% CI)
APACHE II score
a
< 13 (n = 35) 1.00 1.00 1.00
13-17 (n = 38) 2.51 (0.53, 11.88) 1.43 (0.44, 4.67) 1.46 (0.58, 3.71)
> 17 (n = 34) 3.21 (0.69, 14.92) 1.74 (0.48, 6.30) *3.20 (1.22, 8.40)*
Child-Pugh score
b
< 9 (n = 42) 1.00 1.00 1.00
9-11 (n = 45) 1.85 (0.46, 7.47)0 1.58 (0.52, 4.94) 2.21 (0.94, 5.20)
> 11 (n = 20) *4.63 (1.16, 18.52)* 0*4.46 (1.34, 14.83)* **6.83 (2.58, 18.07)*
MELD score
c
< 15 (n = 38) 1.00 1.00 1.00
15-20 (n = 33) 1.86 (0.29, 11.95) c2.60 (0.59, 11.53) 1.88 (0.71, 4.97)
> 20 (n = 36) *8.14 (1.56, 42.55)* c*6.01 (1.55, 23.70)* *3.61 (1.48, 8.80)*
Note.─ *Statistical significance (p < 0.05)
CI = confidence interval, TIPS = transjugular intrahepatic portosystemic shunt, APACHE II = acute physiology and chronic health evaluation, MELD =
model for end-stage liver disease, INR = international normalized ratio, WBC = white blood cell 
aAdjusted for sex, age, candidate confounding factors from univariate analysis and components of Child-Pugh or MELD scores (bilirubin level, albumin
level, INR, ascites and encephalopathy).
bAdjusted for sex, age, candidate confounding factors from univariate analysis and components of APACHE II or MELD scores (creatinine level, Na
+ level,
K
+ level, hematocrit and WBC count).
cAdjusted for sex, age, candidate confounding factors from univariate analysis and components of APACHE II score or Child-Pugh score (Na
+ level, K
+
level, hematocrit, WBC count, albumin level, ascites and encephalopathy).was uncertainty in some cases.
Baseline characteristics of the participants are shown in
Table 1. The majority of patients had viral hepatitis (n =
73, 68%). After TIPS placement, the average portal
venous pressure decreased from 32.84 to 21.12 mmHg (p
< 0.001) and the PSG decreased from 26.96 to 11.27
mmHg (p < 0.001).
For 38 patients who were subjected to follow-up for
more than six months, shunt dysfunction was identified in
12 patients and 16 sessions of re-intervention with
placement of additional stents were performed.
Survival Analysis
No patient died during the TIPS procedure, but 82
(77%) patients died during the follow-up period. Thirty
(28%) patients died within 30 days, 37 (35%) patients died
within 60 days and 53 (50%) patients died within 360
days. Causes of death included hypovolemic shock (nine
patients), hepatic failure (31 patients), septic shock (29
patients), respiratory failure (eight patients), renal failure
(one patient) and other causes (four patients).
As shown in Table 2, univariate analysis demonstrated
that mortality after 30, 60 and 360 days increased signifi-
cantly with increasing laboratory values for the creatinine
level, PT, INR, APTT, BUN, WBC count and pre-TIPS
placement and post-TIPS placement portal and central
venous pressure levels (p < 0.05). Decreasing levels of
albumin and hemoglobin and a decreased hematocrit were
also associated with increased 30-day mortality (p < 0.05).
Patients with encephalopathy or hepatorenal syndrome, or
Tzeng et al.
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Fig. 1. Kaplan-Meier 360-day survival curves based on (A) acute
physiology and chronic health evaluation scores, (B) Child-Pugh
scores and (C) model for end-stage liver disease scores. Tertile
difference for 30-day, 60-day and 360-day survival was significant
(log-rank test, all p < 0.01).
Survival Days
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
 
R
a
t
e
Survival Days
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
 
R
a
t
e
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
 
R
a
t
e
Survival Days
APACHE II
MELD score
Child-Pugh scorewho received mechanical ventilation or inotropic agents
had a worse prognosis (p < 0.05).
For 30-day survival, patients in the first (< 13) and
second (13-17) APACHE II tertiles had similar survival
rates, but patients in the third tertile (> 17) had poor
survival (log-rank test, p < 0.001). The three Child-Pugh
tertiles (< 9, 9-11 and > 11) showed a significant difference
in survival (log-rank test, p < 0.001). Patients in the first (<
15) and second (15-20) MELD tertiles had similar survival
rates, but overall survival was worse in the third (> 20)
tertile (log-rank test, p < 0.001). For 60-day and 360-day
survival, the survival rate differed among tertiles for
APACHE II (Fig. 1A), Child-Pugh (Fig. 1B) and MELD
(Fig. 1C) scores, with all differences significant (log-rank
test, all p < 0.001).
The hazard ratios for survival using the three scoring
systems are shown in Table 3. Patients with APACHE II
scores > 17 had a three-fold higher risk of mortality at 360
days as compared to patients with APACHE II scores < 17
(p < 0.05). Patients with Child-Pugh scores > 11 had an
approximately four-fold to six-fold higher risk of mortality
at all time points as compared to patients with Child-Pugh
scores < 9 (p < 0.05). Patients with MELD scores > 20 had
an approximately four-fold to eight-fold higher risk of
mortality at all time points as compared to patients with
MELD scores < 15 (p < 0.05).
C-Statistics
The accuracy of prediction of survival by each model
was tested with the area-under-the-curve (AUC) (Fig. 2),
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Fig. 2. Receiver operating characteristics curves for acute physiol-
ogy and chronic health evaluation, Child-Pugh and model for end-
stage liver disease for (A) 30-day, (B) 60-day, and (C) 360-day
mortality.
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Child-Pugh
MELD
Source of Curve
APACHE II
Child-Pugh
MELD
Source of Curve
APACHE II
Child-Pugh
MELD
Source of Curveor C-statistic (Table 4). Small differences between the three
scores were found, but none achieved statistical signifi-
cance (all p > 0.05).
DISCUSSION
Existing scoring systems that are used to predict patient
mortality after TIPS placement, including the APACHE II,
Child-Pugh and MELD, were derived largely in non-Asian
patient populations. Our results suggest that when these
models are used for Taiwanese patients, the prediction of
mortality is less than optimal. All of the scoring systems
were able to predict mortality to some extent, but the
APACHE II score was only useful to predict mortality at
360 days. Both the Child-Pugh and the MELD scores could
predict mortality at 30 days, 60 days and 360 days, with
the MELD score performing marginally better as compared
to the Child-Pugh score, based on the hazard ratio of
patients in the highest risk tertile. However, all of the
current grading schemes leave room for improvement as
demonstrated in this population of Taiwanese patients.
Univariate analysis of 15 different factors was performed
and found all factors to be related to 30-day mortality.
Other studies of 30-day mortality after emergency TIPS
placement have also shown many risk factors determined
by the use of univariate analysis (10-12, 16). The most
consistently reported risk factors are the bilirubin level, PT
(or some other measure of bleeding time) and the need for
ventilator support. Our results largely concur with these
findings. The study (16), in which population was most
similar to ours (30-day mortality after TIPS placement for
acute bleeding varices in patients with virally-caused
cirrhosis) showed agreement with our findings for three
risk factors: creatinine level, albumin level and PT. Final
univariate analyses indicated that hepatorenal syndrome,
use of inotropic agents and mechanical ventilation were
associated with elevated 30-day mortality (all p < 0.05).
Prediction of mortality was roughly equivalent for the
three scoring systems according to the C-statistic analysis
of predictive power. The C-statistic for the three scoring
systems to predict 30-day, 60-day and 360-day mortality
were 0.81, 0.75 and 0.78 for the APACHE II scores, 0.74,
0.71 and 0.73 for the Child-Pugh scores and 0.78, 0.78 and
0.74 for the MELD scores, respectively. In general, a C-
statistic of 0.8 to 0.9 indicates excellent predictive accuracy
while a C-statistic of 0.7 to 0.8 is acceptable. By the use of
these criteria, our results suggest that the APACHE II and
MELD systems may be somewhat better than the Child-
Pugh classification for our patients. However, there were
no significant differences between the scoring systems for
pair-wise comparisons. Three other studies, all of elective
patients that had undergone the TIPS procedure, have
compared the predictive power between the use of MELD
and Child-Pugh scores (14-17). In one study, which did not
use C-statistics, the MELD but not the Child-Pugh score
was significantly better to predict survival and three-month
mortality (14). In a second study, C-statistics showed that
MELD (0.71) and Child-Pugh (0.72) scores had similar
predictive power for three-month mortality (15). A third
study reported similar C-statistics for MELD (0.73) and
Child-Pugh (0.78) scores for 30-day mortality (17). 
Differences in the predictive ability between the scoring
systems could arise for a number of reasons. The APACHE
II system emphasizes general physical health; it was
standardized for ICU patients and was intended to predict
early mortality risk for ICU patients. Only one item is
specific to liver disease and liver disease severity is
recorded indirectly, as it affects physiological measure-
ments. The MELD model uses three laboratory test values
and an empirically developed algorithm derived from
these values. The goal of the MELD model is to avoid
subjective judgment and to give greater weight to
extremely abnormal laboratory values. The Child-Pugh
model includes two measurements of the impact of liver
function on other systems, namely ascites and
encephalopathy, in addition to three laboratory values of
liver function. In addition, the Child-Pugh model is consid-
ered easy to use as the model uses a point system for
scoring.
A limitation of this study is that it was retrospective, with
the risk of data misinterpretation. Another limitation is
that we were unable to determine which patients received
beta-blocker therapy, an intervention that could have
affected the portovenous gradient.
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Table 4. Prediction of 30-day, 60-day and 360-day Mortality for APACHE II, Child-Pugh and MELD Models; Values Shown are 
C-Statistics
Variables APACHE II (95% CI) Child-Pugh (95% CI) MELD (95% CI)
30-day survival 0.81 (0.72, 0.88) 0.74 (0.65, 0.82) 0.78 (0.69, 0.85)
60-day survival 0.75 (0.66, 0.83) 0.71 (0.62, 0.80) 0.78 (0.69, 0.86)
360-day survival 0.78 (0.69, 0.85) 0.73 (0.64, 0.81) 0.74 (0.65, 0.82)
Note.─ CI = confidence interval, APACHE II = acute physiology and chronic health evaluation, MELD = model for end-stage liver diseaseIn summary, our results show that a Child-Pugh score >
11 or an MELD score > 20 are predictive of 30-day, 60-
day and 360-day mortality in Asian patients with refrac-
tory variceal hemorrhage treated with the TIPS procedure.
The APACHE II score is not predictive of early mortality
in this patient population.
Acknowledgement
The authors thank Sy-Yu Yeh, MS for medical records
review and collection and collation of data for statistical
analysis, Chin-Li Lu, MS for help in statistical analysis and
R. Grant Steen, PhD for help in drafting the manuscript. 
References
1. Coldwell DM, Ring EJ, Rees CR, Zemel G, Darcy MD, Haskal
ZJ, et al. Multicenter investigation of the role of transjugular
intrahepatic portosystemic shunt in management of portal
hypertension. Radiology 1995;196:335-340
2. Luca A, D’Amico G, La Galla R, Midiri M, Morabito A, Pagliaro
L. TIPS for prevention of recurrent bleeding in patients with
cirrhosis: meta-analysis of randomized clinical trials. Radiology
1999;212:411-421
3. Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau
JM, et al. The transjugular intrahepatic portosystemic stent-
shunt procedure for variceal bleeding. N Engl J Med
1994;330:165-171
4. Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of
transjugular intrahepatic portosystemic shunt for treatment of
portal hypertension and its complications: a conference
sponsored by the National Digestive Diseases Advisory Board.
Hepatology 1995;22:1591-1597
5. Banares R, Casado M, Rodriguez-Laiz JM, Camunez F, Matilla
A, Echenagusia A, et al. Urgent transjugular intrahepatic
portosystemic shunt for control of acute variceal bleeding. Am J
Gastroenterol 1998;93:75-79
6. Sanyal AJ, Freeman AM, Lutetic VA, Purdum PP, Shiffman
ML, Tisnado J, et al. Transjugular intrahepatic portosystemic
shunts for patients with active variceal hemorrhage unrespon-
sive to sclerotherapy. Gastroenterology 1996;111:138-146
7. McCormick PA, Dick R, Panagou EB, Chin JK, Greenslade L,
McIntyre N, et al. Emergency transjugular intrahepatic portasys-
temic stent shunting as salvage treatment for uncontrolled
variceal bleeding. Br J Surg 1994;81:1324-1327
8. Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel
NH, et al. Determinants of mortality in patients with advances
cirrhosis after transjugular intrahepatic portosystemic shunting.
Gastroenterology 2000;118:138-144
9. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter
Borg PC. A model to predict poor survival in patients undergo-
ing transjugular intrahepatic portosystemic shunts. Hepatology
2000;31:864-871
10. Rubin RA, Haskal ZJ, O’Brien CB, Cope C, Brass CA.
Transjugular intrahepatic portosystemic shunting: decreased
survival for patients with high APACHE II scores. Am J
Gastroenterol 1995;90:556-563
11. Patch D, Nikolopoulou V, McCormick A, Dick R, Armonis A,
Wannamethee G, et al. Factors related to early mortality after
transjugular intrahepatic portosystemic shunt for failed
endoscopic therapy in acute variceal bleeding. J Hepatol
1998;28:454-460
12. Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early
mortality after transjugular intrahepatic portosystemic shunts:
results of a multivariate analysis. J Vasc Interv Radiol
2002;13:155-161
13. Brensing KA, Raab P, Textor J, Gorich J, Schiedermaier P,
Strunk H, et al. Prospective evaluation of a clinical score for 60-
day mortality after transjugular intrahepatic portosystemic
stent-shunt: Bonn TIPSS early mortality analysis. Eur J
Gastroenterol Hepatol 2002;14:723-731
14. Montgomery A, Ferral H, Vasan R, Postoak DW. MELD score
as a predictor of early death in patients undergoing elective
transjugular intrahepatic portosystemic shunt (TIPS) procedures.
Cardiovasc Intervent Radiol 2005;28:307-312
15. Yoon CJ, Chung JW, Park JH. Transjugular intrahepatic
portosystemic shunt for acute variceal bleeding in patients with
viral liver cirrhosis: predictors of early mortality. AJR Am J
Roentgenol 2005;185:885-889
16. Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild
HH, et al. Comparison of MELD, Child-Pugh, and Emory model
for the prediction of survival in patients undergoing transjugular
intrahepatic portosystemic shunting. Am J Gastroenterol
2003;98:1167-1174
17. Angermayr B, Cejna M, Karnel F, Gshwantler M, Koenig F,
Pidlich J, et al. Child-Pugh versus MELD score in predicting
survival in patients undergoing transjugular intrahepatic
portosystemic shunt. Gut 2003;52:879-885
APACHE II versus Child-Pugh versus MELD Scores in Predicting Mortality after TIPS Procedures in Asian Patients
Korean J Radiol 10(5), Sep/Oct 2009 489